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a b s t r a c t
Clozapine is an antipsychotic known for its superior efﬁcacy in treating drug-resistant Schizophrenia.
However, Clozapine induces various side effects such as hyperglycemia, agranulocytosis, weight gain etc.
The mechanisms of these Clozapine-induced side effects have remained largely elusive though an
important role is ascribed to 5-HT2A (Serotonin receptor subtype-2A). In this pilot study, we report for
the ﬁrst time that the 5-HT2A ‘global’ knockout mice (Htr2a/) are resistant to the Clozapine-induced
hyperglycemia. Importantly though, the Htr2a/ mice exhibit near normal basal glucose metabolism
in the glucose tolerance tests. Collectively, the Htr2a/ mice provide an important tool to study the
Clozapine-induced hyperglycemia.
© 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Among atypical antipsychotics, Clozapine is considered to be
the most effective, clinically. However, it is associated with the
increased risk of metabolic disorders such as weight gain and
glucose dysregulation.1e4
Clozapine acts as an inverse agonist/antagonist at the Serotonin
receptor 5-HT2A, blocking the canonical signaling.5 However,
recently Clozapinewas shown to have agonist-like properties at the
5-HT2A.6,7 5-HT2A knockout mice (Htr2a/) are also resistant to a
side effect of Clozapine, i.e. Sedation.8,9 Here we have studied the
response of the Htr2a/mice to Clozapine-induced metabolic side
effects, particularly the acute Clozapine-induced hyperglycemia
(CIH). We have used global Htr2a/ mice, where 5-HT2A is absent
from all tissues from fertilization.
CIH is observed in patients and also in animal models.2e4 CIH is
reversible and ceases with the treatment.4 Therefore it would be
very useful to study the acute form of CIH, disentangled from the
chronic side effects such as weight gain. The mechanism of CIH
with respect to its receptor dependence, if any, has not been well
studied. 5-HT2A is one of the potential candidates for CIH.
5-HT2A is expressed in the brain10 and in several peripheral
organs.11 5-HT2A agonists have been shown to increase glucose
uptake, which is inhibited by the 5-HT2 class antagonist- Ketan-
serin.11 Moreover, Ketanserin impairs insulin sensitivity in healthy
volunteers.12 Conversely, 5-HT2A agonists have also been shown to
cause hyperglycemia in animals.13 Since these ligands can have
multiple targets and distinct pharmacokinetics, the role of 5-HT2A
in CIH is hard to discern. Therefore, we used the Htr2a/ mice to
address this question.9
The Htr2a/ strain was maintained under standard laboratory
conditions.9 Male mice, minimum 3 months old, were used for the
experiments. The mice were obtained from heterozygous matings
and genotyped as described in Joshi et al., 2016.9 Mice were
randomly assigned to either the vehicle or the drug group for CIH.
All experiments were approved by the Institutional Animal Ethics
Committee (NCBS-IAE-2016/15(E)).
For CIHwe arrived at a dose of 5mg/kg of Clozapine based on the
following a) at this dose our group and others have reported
differences between Htr2a/ and Htr2aþ/þ mice for Clozapine-
induced sedation b) at 5 mg/kg of Clozapine we have observed 5-
HT2A dependent Clozapine-speciﬁc cellular responses in the mice
brain (Joshi et al., BioRxiv 226050) c) and previous literature.14 For
the CIH test, mice were not allowed to feed for 6 hours prior to the
drug administration to avoid immediate effects of feeding on the
blood glucose levels (BGL) (Fig. 1a). Clozapine (0444, Tocris, Bristol,
UK) was administered intraperitoneally, and blood was obtained at
the deﬁned intervals from the tail tip. The BGLwere determinedwith
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‘GlucoseOneTouchUltra 2meter’ (Johnson and Johnson,New Jersey,
USA). At least two readings were acquired for each time point.
After 30 and 60minutes of Clozapine administration, theHtr2aþ/þ
group showed a drastic increase in the BGL compared to the vehicle
group, indicating CIH (Fig. 1b,c). However, theHtr2a/mice showed
very little or no increase in the BGL. The increase in the BGL in the
Htr2aþ/þ group was signiﬁcantly higher than the Htr2a/ group
(Fig. 1b,c). At 120minutes post-drug administration, the BGL inmost
of the Clozapine-treated Htr2aþ/þ group approached basal levels.
Thus, at 120 minutes, the Htr2aþ/þ mice exhibited a trend of CIH
compared to the vehicle and the Htr2a/ group (Fig. 1d). Therefore
our results suggest that the lack of 5-HT2A modulates CIH.
Importantly, our experiments were conducted with littermates
and the baseline bodyweights and BGL of theHtr2aþ/þ andHtr2a/
mice were comparable to each other (Fig. 1e,f). These baseline
measurements were determined just before the administration of
Clozapine/Vehicle, and the data was pooled from all the Htr2aþ/þ
and Htr2a/ mice used.
To account for any pre-existing differences in the glucose
metabolism of the Htr2aþ/þ and Htr2a/ mice, we conducted
glucose tolerance tests (GTT). For GTT, mice were food deprived
overnight, and blood samples were obtained as described above. To
reduce the number of animals, mice were subjected to the GTT,
followed by the CIH test, with a minimum interval of a one-week.
Glucose (1 mg/kg) (G8270, SigmaeAldrich, USA) was adminis-
tered intraperitoneally.
Glucose administration produced the expected and similar
patterns of the BGL in both the Htr2aþ/þ andHtr2a/mice (Fig. 2a).
We further analyzed the total area under the curve (AUC). However,
it was statistically indistinguishable between the Htr2aþ/þ and
Htr2a/mice (Fig. 2b). These results suggest that the basal glucose
metabolism in the Htr2a/ and Htr2aþ/þmice is largely similar and
unlikely to explain the differences seen with CIH.
Interestingly, there was a subtle yet signiﬁcant difference
between the baseline BGL of the Htr2aþ/þ and Htr2a/mice (94.89
(±3.8) and 120.4 (±7.5) mg/dL, respectively), after 12 h of food
deprivation (Fig. 2a). 5-HT2A expression in the liver and muscles is
thought to regulate glucose metabolism.11,15 Thus, it is possible that
the lack of 5-HT2A exerts subtle effects on glucose metabolism
which builds up over prolonged fasting. Further experiments on the
basal metabolism of the Htr2a/ mice under different dietary
regime might shed some light on this aspect.
Taken together this report presents theHtr2a/mice as a useful
tool to investigate some of the pathways underlying the acute form
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Fig. 1. Htr2a/mice are protected against the CIH. a) Schematic representation of the protocol for CIH. b), c) and d) The graphs show Clozapine-induced increase in the BGL- 30,
60 and 120 min after the drug/vehicle administration. The Htr2aþ/þmice showed a signiﬁcant increase in the BGL compared to the vehicle-treated group and the Htr2a/ group at
30 and 60 min time points. After 120 min of drug administration, the Htr2aþ/þmice only showed a trend towards increased BGL, which did not reach signiﬁcance. two-way ANOVA
e *Comparison with 0 mg/kg, # comparison with the Htr2aþ/þ at the same dose. e & f) Basal body weight and BGL did not differ between the Htr2aþ/þ and Htr2a/mice. Student's
t-test. (n. s. e not signiﬁcant). Number in the bar represents ‘N's. Data shown as Mean ± SEM. *p < 0.05, **p < 0.001. (two-way ANOVA, 30 min post-drug treatment: effect of drug,
F(1,36) ¼ 4.87, p ¼ 0.0337, genotype, F(1,36) ¼ 3.62, p ¼ 0.0648, interaction, F(1,36) ¼ 4.34, p ¼ 0.0444, 60 min post-drug treatment: effect of drug, F(1,36) ¼ 17.04, p ¼ 0.0002,
genotype, F(1,36) ¼ 7.06, p ¼ 0.0116, interaction, F(1,36) ¼ 2.72, p ¼ 0.1077).
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Fig. 2. Htr2aþ/þ and Htr2a/ mice show similar basal glucose metabolism. a) The Htr2aþ/þ and Htr2a/ mice showed similar and a clear increase in the BGL, 30 min after
glucose administration. two-way ANOVA e *Comparison with 0 mg/kg, # comparison with Htr2aþ/þ at the same dose. (Data was transformed for two-way ANOVA, effect of time,
F(3,114) ¼ 217.9, p < 0.0001, genotype, F(1,38) ¼ 9.147, p ¼ 0.0044, interaction, F(3,114) ¼ 4.501, p ¼ 0.0051). b) The Htr2aþ/þ and Htr2a/ mice showed no difference in the Area
Under the Curve in Figure 2a (AUC). Student's t-test. (n. s. e not signiﬁcant). Number in the bar represents ‘N's. Data shown as Mean ± SEM. ****p < 0.0001.
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of CIH. It would be of interest to determine if the observed effects in
the Htr2a/ mice are a result of a direct interaction of Clozapine
with the 5-HT2A or a secondary effect. It would also be vital to
determine if any compensatory changes in the expression of other
GPCRs (such as 5-HT1A, 5-HT2B, 5-HT2C, and H1 receptor etc.) and
the endocrine system are present in the Htr2a/ mice.
Since we have used a global knockoutof the 5-HT2A, we cannot
dissect the roles played by speciﬁc tissues in CIH. Genetic or virus-
induced tissue-speciﬁc deletion of 5-HT2A would be appropriate in
this regard. While this study has explored very speciﬁc, and a
limited aspect of the metabolic side effects of Clozapine, namely
hyperglycemia, it should still serve as a stepping stone to under-
stand the chronic metabolic side effects of Clozapine.
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